SDB-005
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H22N2O2 |
| Molar mass | 358.441 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SDB-005 (also known as NA-PINAC using systematic EUDA nomenclature)[1] is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[2] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used by Samuel D. Bannister for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006, pictured. It is systematically named PH-PICA (Phen-1-yl 1-Pentyl-1H-indazole-3-carboxamide. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM)[3] but has significant chemical differences; an indazole ring (instead of indole ring), a carboxamide linker (instead of carboxylate ester) and linked phenyl (instead of naphtyl) group).
However, SDB-005 was subsequently used as the name for the indazole-3-napthyl-carboxylate compound when it was sold in Europe as a designer drug. Because of this, it was entered into the EMCDDA synthetic drug database under this name.[4] The UK Forensic Early Warning System reported a detection of SDB-005 in December 2017 as the first occurrence of naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate (NA-PINAC) in the UK.[5] Many online sources now list SDB-005 as naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (NA-PINAC).[6][7]
Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
See also
[edit]References
[edit]- ↑ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325.
- ↑ "SDB-005". Cayman Chemical. Retrieved 27 June 2015.
- ↑ Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, et al. (July 2013). "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience. 4 (7): 1081–92. doi:10.1021/cn400035r. PMC 3715837. PMID 23551277.
- ↑ EWS_EU: Neue Psychoaktive Substanzen, April 2015
- ↑ "Annual report on the Home Office forensic early warning system (FEWS), 2017 to 2018". GOV.UK. Retrieved 2026-06-25.
- ↑ "TRC-S210000-1G". www.lgcstandards.com. Retrieved 2026-06-25.
naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate
- ↑ "SDB-005 Monograph" (PDF). DEA SWGDrug Monographs. The Drug Enforcement Administration's Special Testing and Research Laboratory (SWGDrug). 2016-04-04. Retrieved 2026-06-26.
naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate